拉替拉韦强化对接受加强型蛋白酶抑制剂单药治疗的HIV-1感染者影响
研究评估拉替拉韦强化24周对33例接受达芦那韦或洛匹那韦/利托那韦单药维持治疗的HIV-1感染者的病毒持续、免疫激活和炎症标志物的影响。结果显示强化后2-LTR环短暂增加、CD8+ T细胞激活下降、CTLA-4表达暂时升高,残留病毒血症(10-60拷贝/mL)样本数减少,但细胞相关HIV-1 DNA和可溶性炎症标志物无变化。结论提示单药治疗期间存在持续低水平病毒复制,T细胞表型变化与病毒活跃产生相关。
要点
- 拉替拉韦强化使2-LTR环短暂增加,提示单药治疗下存在持续病毒复制。
- 强化后CD8+ T细胞激活水平下降,CTLA-4表达暂时升高。
- 残留病毒血症(10-60拷贝/mL)样本数减少,但HIV-1 DNA和炎症标志物无变化。
核心结论
- 拉替拉韦强化加强型蛋白酶抑制剂单药治疗揭示部分患者存在持续低水平病毒复制并减少残留病毒血症。
- T细胞表型的同步变化提示活跃病毒产生与T细胞激活之间存在关联。
- 这些结果有助于理解临床试验中加强型蛋白酶抑制剂单药治疗疗效低于三联疗法。
研究设计与样本
- 研究评估33例接受达芦那韦或洛匹那韦/利托那韦单药维持治疗的HIV-1感染者,给予拉替拉韦强化24周。
- ClinicalTrials.gov标识:NCT01480713。
主要发现
- 拉替拉韦加入加强型蛋白酶抑制剂单药治疗导致显著比例参与者2-LTR环短暂增加。
- CD8+ T细胞激活水平下降,外周T淋巴细胞耗竭标志物CTLA-4表达暂时升高。
- 与单药治疗期间样本相比,强化后残留病毒血症(10-60 HIV-1 RNA拷贝/mL)样本数减少。
- 外周CD4+ T细胞中细胞相关HIV-1 DNA及可溶性炎症标志物(CD14、IP-10、IL-6、C反应蛋白和D-二聚体)无变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Monotherapy with ritonavir-boosted PIs (PI/r) has been used to simplify treatment of HIV-1-infected patients. In previous studies raltegravir intensification evidenced ongoing viral replication and reduced T cell activation, preferentially in subjects receiving PI-based triple ART. However, data about low-level viral replication and its consequences in patients receiving PI/r monotherapy are scarce. METHODS: We evaluated the impact of 24 weeks of intensification with raltegravir on markers of viral persistence, cellular immune activation and inflammation biomarkers in 33 patients receiving maintenance PI/r monotherapy with darunavir or lopinavir boosted with ritonavir. ClinicalTrials.gov identifier: NCT01480713. RESULTS: The addition of raltegravir to PI/r monotherapy resulted in a transient increase in 2-LTR (long-terminal repeat) circles in a significant proportion of participants, along with decreases in CD8+ T cell activation levels and a temporary increase in the expression of the exhaustion marker CTLA-4 in peripheral T lymphocytes. Intensification with raltegravir also reduced the number of samples with intermediate levels of residual viraemia (10-60 HIV-1 RNA copies/mL) compared with samples taken during PI/r monotherapy. However, there were no changes in cell-associated HIV-1 DNA in peripheral CD4+ T cells or soluble inflammatory biomarkers (CD14, IP-10, IL-6, C-reactive protein and D-dimer). CONCLUSIONS: Intensification of PI/r monotherapy with raltegravir revealed persistent low-level viral replication and reduced residual viraemia in some patients during long-term PI/r monotherapy. The concomitant change in T cell phenotype suggests an association between active viral production and T cell activation. These results contribute to understanding the lower efficacy rates of PI/r monotherapies compared with triple therapies in clinical trials.
引用
- Puertas MC, Gómez-Mora E, Santos JR, et al. Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs. J Antimicrob Chemother. 2018. PMID: 29635527. doi:10.1093/jac/dky106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。